Using previously validated immune gene signatures from bulk RNA datasets to estimate immune cell abundances (42), we found that B2M and CD1D but not CD1B were significantly enriched on both tumor and DCs cells from patients responding to ICT (Figure 2E). The gene discussed is CD1B; the disease is neoplasm.